Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families

Author(s): Yue-Ping Wang*, Fei-Ping Li*, Hui-Hong Wang, Xu-Dong Fang, Zai-Sheng Zhu, Yong-Liang Chen* and Xiao-Ping Qi*

Volume 22, Issue 3, 2022

Published on: 11 January, 2022

Page: [339 - 347] Pages: 9

DOI: 10.2174/2214083203666210826094602

Price: $65

Abstract

Background: Multiple endocrine neoplasia type 2A (MEN 2A) is mainly caused by germline RET codon C634 mutation and is characterized by Medullary Thyroid Carcinoma (MTC), pheochromocytoma (PHEO), and hyperparathyroidism (HPTH). The early diagnosis and initial normative treatment are helpful for the long-term outcome of MEN2A.

Methods: Three index cases and their 29 relatives from three families with MEN2A were included in this study. Genetic screening was performed on all participants. Demographic, clinical profiles, tumor histopathologic features, and follow-up records were systematically analyzed.

Results: In total, RET C634Y mutation was identified in 10 individuals (10/32, 31.3%). Among them, 5 presented with MTC symptoms, whereas the other 5 did not show apparent clinical manifestation, and all were subjected to thyroidectomy with varying neck dissection. Compared to individuals in the former, the latter benefited greatly from RET screening with significantly younger age at diagnosis of MTC and surgery (18.1 ± 13.8 years vs. 39.0 ± 14.1 years, P =0.045), and lessaggressive MTC behavior (size: 0.74 vs. 2.82 cm, P =0.026; LN+/resected: 20.0% vs. 100.0%, P =0.048) and also lower recurrence rate of MTC (20.0% vs. 100.0%, P =0.048). The PHEO was identified in 6 of the 10 carriers (60.0%), and all had undergone adrenal-sparing surgery. During the 10 years of follow-up, one (16.7%) developed recurrence of PHEO.

Conclusion: Integrated RET screening, serum calcitonin, and plasma metanephrine/ normetanephrine levels can facilitate the early diagnosis and standardized MTC/PHEO surgery to improve the prognosis of MEN2A. Laparoscopic adrenal-sparing surgery prior to the bilateral total thyroidectomy is a preferred surgical approach for PHEO.

Keywords: Multiple endocrine neoplasia type 2A, medullary thyroid carcinoma, pheochromocytoma, RET proto-oncogene, prophylactic thyroidectomy, adrenal sparing surgery.

« Previous Next »
Graphical Abstract

[1]
Wells, S.A., Jr; Pacini, F.; Robinson, B.G.; Santoro, M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: An update. J. Clin. Endocrinol. Metab., 2013, 98(8), 3149-3164.
[http://dx.doi.org/10.1210/jc.2013-1204] [PMID: 23744408]
[2]
Moline, J.; Eng, C. Multiple endocrine neoplasia type 2: An overview. Genet. Med., 2011, 13(9), 755-764.
[http://dx.doi.org/10.1097/GIM.0b013e318216cc6d] [PMID: 21552134]
[3]
Tsang, V.H.; Tacon, L.J.; Learoyd, D.L.; Robinson, B.G. Pheochromocytomas in multiple endocrine neoplasia type 2. Recent Results Cancer Res., 2015, 204, 157-178.
[http://dx.doi.org/10.1007/978-3-319-22542-5_7] [PMID: 26494388]
[4]
Frank-Raue, K.; Rybicki, L.A.; Erlic, Z.; Schweizer, H.; Winter, A.; Milos, I.; Toledo, S.P.; Toledo, R.A.; Tavares, M.R.; Alevizaki, M.; Mian, C.; Siggelkow, H.; Hüfner, M.; Wohllk, N.; Opocher, G.; Dvořáková, S.; Bendlova, B.; Czetwertynska, M.; Skasko, E.; Barontini, M.; Sanso, G.; Vorländer, C.; Maia, A.L.; Patocs, A.; Links, T.P.; de Groot, J.W.; Kerstens, M.N.; Valk, G.D.; Miehle, K.; Musholt, T.J.; Biarnes, J.; Damjanovic, S.; Muresan, M.; Wüster, C.; Fassnacht, M.; Peczkowska, M.; Fauth, C.; Golcher, H.; Walter, M.A.; Pichl, J.; Raue, F.; Eng, C.; Neumann, H.P. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum. Mutat., 2011, 32(1), 51-58.
[http://dx.doi.org/10.1002/humu.21385] [PMID: 20979234]
[5]
Castinetti, F.; Qi, X.P.; Walz, M.K.; Maia, A.L.; Sansó, G.; Peczkowska, M.; Hasse-Lazar, K.; Links, T.P.; Dvorakova, S.; Toledo, R.A.; Mian, C.; Bugalho, M.J.; Wohllk, N.; Kollyukh, O.; Canu, L.; Loli, P.; Bergmann, S.R.; Biarnes Costa, J.; Makay, O.; Patocs, A.; Pfeifer, M.; Shah, N.S.; Cuny, T.; Brauckhoff, M.; Bausch, B.; von Dobschuetz, E.; Letizia, C.; Barczynski, M.; Alevizaki, M.K.; Czetwertynska, M.; Ugurlu, M.U.; Valk, G.; Plukker, J.T.; Sartorato, P.; Siqueira, D.R.; Barontini, M.; Szperl, M.; Jarzab, B.; Verbeek, H.H.; Zelinka, T.; Vlcek, P.; Toledo, S.P.; Coutinho, F.L.; Mannelli, M.; Recasens, M.; Demarquet, L.; Petramala, L.; Yaremchuk, S.; Zabolotnyi, D.; Schiavi, F.; Opocher, G.; Racz, K.; Januszewicz, A.; Weryha, G.; Henry, J.F.; Brue, T.; Conte-Devolx, B.; Eng, C.; Neumann, H.P. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: An international retrospective population-based study. Lancet Oncol., 2014, 15(6), 648-655.
[http://dx.doi.org/10.1016/S1470-2045(14)70154-8] [PMID: 24745698]
[6]
Alevizaki, M.; Saltiki, K. Primary Hyperparathyroidism in MEN2 Syndromes. Recent Results Cancer Res., 2015, 204, 179-186.
[http://dx.doi.org/10.1007/978-3-319-22542-5_8] [PMID: 26494389]
[7]
Elisei, R.; Alevizaki, M.; Conte-Devolx, B.; Frank-Raue, K.; Leite, V.; Williams, G.R. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur. Thyroid J., 2013, 1(4), 216-231.
[http://dx.doi.org/10.1159/000346174] [PMID: 24783025]
[8]
Li, S.Y.; Ding, Y.Q.; Si, Y.L.; Ye, M.J.; Xu, C.M.; Qi, X.P. 5P strategies for management of multiple endocrine neoplasia type 2: a paradigm of precision medicine. Front. Endocrinol. (Lausanne), 2020, 11, 543246.
[http://dx.doi.org/10.3389/fendo.2020.543246] [PMID: 33071967]
[9]
Qi, X.P.; Jin, B.Y.; Li, P.F.; Wang, S.; Zhao, Y.H.; Cao, Z.L.; Yu, X.H.; Cheng, J.; Fang, X.D.; Zhao, J.Q. RET S409Y germline mutation and associated medullary thyroid carcinoma. Thyroid, 2019, 29(10), 1447-1456.
[http://dx.doi.org/10.1089/thy.2018.0385] [PMID: 31364476]
[10]
Machens, A.; Dralle, H. Therapeutic effectiveness of screening for multiple endocrine neoplasia Type 2A. J. Clin. Endocrinol. Metab., 2015, 100(7), 2539-2545.
[http://dx.doi.org/10.1210/jc.2015-1689] [PMID: 25946031]
[11]
Wells, S.A., Jr; Asa, S.L.; Dralle, H.; Elisei, R.; Evans, D.B.; Gagel, R.F.; Lee, N.; Machens, A.; Moley, J.F.; Pacini, F.; Raue, F.; Frank-Raue, K.; Robinson, B.; Rosenthal, M.S.; Santoro, M.; Schlumberger, M.; Shah, M.; Waguespack, S.G. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015, 25(6), 567-610.
[http://dx.doi.org/10.1089/thy.2014.0335] [PMID: 25810047]
[12]
Qi, X.P.; Peng, J.Z.; Yang, X.W.; Zao, Z.L.; Yu, X.H.; Fang, X.D.; Zhang, D.H.; Zhao, J.Q. The RET C611Y mutation causes MEN 2A and associated cutaneous. Endocr. Connect., 2018, 7(9), 998-1005.
[http://dx.doi.org/10.1530/EC-18-0220] [PMID: 30300539]
[13]
Kloos, R.T.; Eng, C.; Evans, D.B.; Francis, G.L.; Gagel, R.F.; Gharib, H.; Moley, J.F.; Pacini, F.; Ringel, M.D.; Schlumberger, M.; Wells, S.A., Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 2009, 19(6), 565-612.
[http://dx.doi.org/10.1089/thy.2008.0403] [PMID: 19469690]
[14]
Lenders, J.W.; Duh, Q.Y.; Eisenhofer, G.; Gimenez-Roqueplo, A.P.; Grebe, S.K.; Murad, M.H.; Naruse, M.; Pacak, K.; Young, W.F.Jr. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 2014, 99(6), 1915-1942.
[http://dx.doi.org/10.1210/jc.2014-1498] [PMID: 24893135]
[15]
Edge, S.B.; Compton, C.C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. In: Ann. Surg. Oncol; , 2010; 17, pp. (6)1471-1474.
[16]
Qi, X.P.; Chen, X. L.; Ma, J.M.; Du, Z.F.; Fei, J.; Yang, C.P.; Cheng, J.; Song, Q.Z.; Han, J.S.; Jin, H.Y.; Chen, Z.G.; Wang, J.Q.; Yang, Y.P.; Ying, R.B.; Liu, W.T.; Zhao, Y.; Chen, C.Y.; Jiang, H.L.; Ke, H.P.; Zhang, X.N. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China. Thyroid, 2012, 22(12), 1257-1265.
[http://dx.doi.org/10.1089/thy.2012.0134] [PMID: 23210566]
[17]
Chen, S.; Li, S.; Zhang, J.; Zhang, L.; Chen, Y.; Wang, L.; Jin, L.; Hu, Y.; Qi, X.; Huang, H.; Xu, C. Preimplantation genetic diagnosis of multiple endocrine neoplasia type 2A using informative markers identified by targeted sequencing. Thyroid, 2018, 28(3), 281-287.
[http://dx.doi.org/10.1089/thy.2017.0200] [PMID: 29378479]
[18]
Filetti, S.; Durante, C.; Hartl, D.; Leboulleux, S.; Locati, L.D.; Newbold, K.; Papotti, M.G.; Berruti, A. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2019, 30(12), 1856-1883.
[http://dx.doi.org/10.1093/annonc/mdz400] [PMID: 31549998]
[19]
Machens, A.; Dralle, H. Advances in risk-oriented surgery for multiple endocrine neoplasia type 2. Endocr. Relat. Cancer, 2018, 25(2), T41-T52.
[http://dx.doi.org/10.1530/ERC-17-0202] [PMID: 28883084]
[20]
de Jong, M. Children are at a high risk of hypocalcaemia and hypoparathyroidism after total thyroidectomy. J. Pediatr. Surg., 2020, 55(7), 1260-1264.
[PMID: 31383578]
[21]
Meltzer, C.; Hull, M.; Sundang, A.; Adams, J.L. Association between annual surgeon total thyroidectomy volume and transient and permanent complications. JAMA Otolaryngol. Head Neck Surg., 2019, 145(9), 830-837.
[http://dx.doi.org/10.1001/jamaoto.2019.1752] [PMID: 31343681]
[22]
Gruber, L.M.; Hartman, R.P.; Thompson, G.B.; McKenzie, T.J.; Lyden, M.L.; Dy, B.M.; Young, W.F.; Bancos, I. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J. Clin. Endocrinol. Metab., 2019, 104(5), 1386-1393.
[http://dx.doi.org/10.1210/jc.2018-01707] [PMID: 30462226]
[23]
Neumann, H.P.H.; Young, W.F., Jr; Eng, C. Pheochromocytoma and paraganglioma. N. Engl. J. Med., 2019, 381(6), 552-565.
[http://dx.doi.org/10.1056/NEJMra1806651] [PMID: 31390501]
[24]
Neumann, H.P.H.; Tsoy, U.; Bancos, I.; Amodru, V.; Walz, M.K.; Tirosh, A.; Kaur, R.J.; McKenzie, T.; Qi, X.; Bandgar, T.; Petrov, R.; Yukina, M.Y.; Roslyakova, A.; van der Horst-Schrivers, A.N.A.; Berends, A.M.A.; Hoff, A.O.; Castroneves, L.A.; Ferrara, A.M.; Rizzati, S.; Mian, C.; Dvorakova, S.; Hasse-Lazar, K.; Kvachenyuk, A.; Peczkowska, M.; Loli, P.; Erenler, F.; Krauss, T.; Almeida, M.Q.; Liu, L.; Zhu, F.; Recasens, M.; Wohllk, N.; Corssmit, E.P.M.; Shafigullina, Z.; Calissendorff, J.; Grozinsky-Glasberg, S.; Kunavisarut, T.; Schalin-Jäntti, C.; Castinetti, F.; Vlcek, P.; Beltsevich, D.; Egorov, V.I.; Schiavi, F.; Links, T.P.; Lechan, R.M.; Bausch, B.; Young, W.F., Jr; Eng, C. Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy. JAMA Netw. Open, 2019, 2(8), e198898.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.8898] [PMID: 31397861]
[25]
Castinetti, F.; Waguespack, S.G.; Machens, A.; Uchino, S.; Hasse-Lazar, K.; Sanso, G.; Else, T.; Dvorakova, S.; Qi, X.P.; Elisei, R.; Maia, A.L.; Glod, J.; Lourenço, D.M., Jr; Valdes, N.; Mathiesen, J.; Wohllk, N.; Bandgar, T.R.; Drui, D.; Korbonits, M.; Druce, M.R.; Brain, C.; Kurzawinski, T.; Patocs, A.; Bugalho, M.J.; Lacroix, A.; Caron, P.; Fainstein-Day, P.; Borson Chazot, F.; Klein, M.; Links, T.P.; Letizia, C.; Fugazzola, L.; Chabre, O.; Canu, L.; Cohen, R.; Tabarin, A.; Spehar Uroic, A.; Maiter, D.; Laboureau, S.; Mian, C.; Peczkowska, M.; Sebag, F.; Brue, T.; Mirebeau-Prunier, D.; Leclerc, L.; Bausch, B.; Berdelou, A.; Sukurai, A.; Vlcek, P.; Krajewska, J.; Barontini, M.; Vaz Ferreira Vargas, C.; Valerio, L.; Ceolin, L.; Akshintala, S.; Hoff, A.; Godballe, C.; Jarzab, B.; Jimenez, C.; Eng, C.; Imai, T.; Schlumberger, M.; Grubbs, E.; Dralle, H.; Neumann, H.P.; Baudin, E. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: An international, multicentre, retrospective study. Lancet Diabetes Endocrinol., 2019, 7(3), 213-220.
[http://dx.doi.org/10.1016/S2213-8587(18)30336-X] [PMID: 30660595]
[26]
Plouin, P.F.; Amar, L.; Dekkers, O.M.; Fassnacht, M.; Gimenez-Roqueplo, A.P.; Lenders, J.W.; Lussey-Lepoutre, C.; Steichen, O. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur. J. Endocrinol., 2016, 174(5), G1-G10.
[http://dx.doi.org/10.1530/EJE-16-0033] [PMID: 27048283]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy